Eva M Del Amo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5126799/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations. International Journal of Pharmaceutics, 2022, 613, 121361.	2.6	14
2	Understanding dexamethasone kinetics in the rabbit tear fluid: Drug release and clearance from solution, suspension and hydrogel formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 172, 53-60.	2.0	13
3	Topical pharmacokinetics of dexamethasone suspensions in the rabbit eye: Bioavailability comparison. International Journal of Pharmaceutics, 2022, 615, 121515.	2.6	7
4	Liposomal sunitinib for ocular drug delivery: A potential treatment for choroidal neovascularization. International Journal of Pharmaceutics, 2022, 620, 121725.	2.6	19
5	Mechanisms of cellular retention of melanin bound drugs: Experiments and computational modeling. Journal of Controlled Release, 2022, 348, 760-770.	4.8	7
6	Comprehensive Ocular and Systemic Pharmacokinetics of Brinzolamide in Rabbits After Intracameral, Topical, and Intravenous Administration. Journal of Pharmaceutical Sciences, 2021, 110, 529-535.	1.6	12
7	Biopharmaceutics of Topical Ophthalmic Suspensions: Importance of Viscosity and Particle Size in Ocular Absorption of Indomethacin. Pharmaceutics, 2021, 13, 452.	2.0	30
8	Current Situation and Challenges in Vitreous Substitutes. Macromolecular Bioscience, 2021, 21, e2100066.	2.1	16
9	Ocular pharmacokinetics of atenolol, timolol and betaxolol cocktail: Tissue exposures in the rabbit eye. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 166, 155-162.	2.0	16
10	Statins for the prevention of proliferative vitreoretinopathy: cellular responses in cultured cells and clinical statin concentrations in the vitreous. Scientific Reports, 2021, 11, 980.	1.6	8
11	Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. Molecular Pharmaceutics, 2020, 17, 588-594.	2.3	7
12	Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits. European Journal of Pharmaceutical Sciences, 2020, 155, 105553.	1.9	19
13	Ocular barriers to retinal delivery of intravitreal liposomes: Impact of vitreoretinal interface. Journal of Controlled Release, 2020, 328, 952-961.	4.8	49
14	PET study of ocular and blood pharmacokinetics of intravitreal bevacizumab and aflibercept in rats. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 154, 330-337.	2.0	7
15	Intravitreal Pharmacokinetic Study of the Antiangiogenic Glycoprotein Opticin. Molecular Pharmaceutics, 2020, 17, 2390-2397.	2.3	1
16	Role of retinal pigment epithelium permeability in drug transfer between posterior eye segment and systemic blood circulation. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 143, 18-23.	2.0	27
17	Distribution of Small Molecular Weight Drugs into the Porcine Lens: Studies on Imaging Mass Spectrometry, Partition Coefficients, and Implications in Ocular Pharmacokinetics. Molecular Pharmaceutics, 2019, 16, 3968-3976.	2.3	20
18	Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties. Drug Discovery Today, 2019, 24, 1446-1457.	3.2	124

Eva M Del Amo

#	Article	IF	CITATIONS
19	Corneal and conjunctival drug permeability: Systematic comparison and pharmacokinetic impact in the eye. European Journal of Pharmaceutical Sciences, 2018, 119, 83-89.	1.9	85
20	Implications of melanin binding in ocular drug delivery. Advanced Drug Delivery Reviews, 2018, 126, 23-43.	6.6	80
21	Esterase activity in porcine and albino rabbit ocular tissues. European Journal of Pharmaceutical Sciences, 2018, 123, 106-110.	1.9	27
22	Impact of Chemical Structure on Conjunctival Drug Permeability: Adopting Porcine Conjunctiva and Cassette Dosing for Construction of In Silico Model. Journal of Pharmaceutical Sciences, 2017, 106, 2463-2471.	1.6	37
23	Pharmacokinetic aspects of retinal drug delivery. Progress in Retinal and Eye Research, 2017, 57, 134-185.	7.3	454
24	Melanin binding study of clinical drugs with cassette dosing and rapid equilibrium dialysis inserts. European Journal of Pharmaceutical Sciences, 2017, 109, 162-168.	1.9	30
25	Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degeneration. Scientific Reports, 2016, 6, 39537.	1.6	45
26	HDAC inhibition in the <i>cpfl1</i> mouse protects degenerating cone photoreceptors <i>in vivo</i> . Human Molecular Genetics, 2016, 25, ddw275.	1.4	39
27	Prediction of Ocular Drug Distribution from Systemic Blood Circulation. Molecular Pharmaceutics, 2016, 13, 2906-2911.	2.3	39
28	Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 215-226.	2.0	108
29	Novel biodegradable polyesteramide microspheres for controlled drug delivery in Ophthalmology. Journal of Controlled Release, 2015, 211, 105-117.	4.8	85
30	Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data. Experimental Eye Research, 2015, 137, 111-124.	1.2	167
31	Applying Linear and Non-Linear Methods for Parallel Prediction of Volume of Distribution and Fraction of Unbound Drug. PLoS ONE, 2013, 8, e74758.	1.1	22
32	Prediction of the Vitreal Half-Life of Small Molecular Drug-Like Compounds. Pharmaceutical Research, 2012, 29, 3302-3311.	1.7	28
33	Prediction of the Corneal Permeability of Drug-Like Compounds. Pharmaceutical Research, 2010, 27, 1398-1407.	1.7	46
34	In vitro–in vivo correlation in p-glycoprotein mediated transport in intestinal absorption. European Journal of Pharmaceutical Sciences, 2009, 36, 200-211.	1.9	48
35	Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. European Journal of Pharmaceutical Sciences, 2008, 35, 161-174.	1.9	287
36	Current and future ophthalmic drug delivery systemsA shift to the posterior segment. Drug Discovery Today, 2008, 13, 135-143.	3.2	356